| abstract |
The present disclosure relates to anti-CD200 antibodies (eg, variable anti-CD200 antibodies with reduced or no executive function) and biomarkers for use in a variety of diagnostic and therapeutic methods, such as desired immunomodulatory effects in humans. The dosage is sufficient to induce the determination of whether one or more antibodies have been administered and / or select a suitable dosing schedule for this patient. |